Opthea Limited (CKDXF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Opthea Limited (CKDXF) with AI Score 53/100 (Hold). Opthea Limited is a clinical-stage biopharmaceutical company focused on developing therapies for eye diseases. Their lead asset, OPT-302, targets wet age-related macular degeneration and diabetic macular edema. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Opthea Limited (CKDXF) Healthcare & Pipeline Overview
Opthea Limited, an Australian clinical-stage biopharmaceutical company, specializes in developing therapies for eye diseases, primarily focusing on its lead asset OPT-302, a novel VEGF-C/D inhibitor for wet age-related macular degeneration and diabetic macular edema, positioning it within the competitive biotechnology landscape.
Investment Thesis
Opthea Limited's investment thesis hinges on the successful clinical development and commercialization of OPT-302. The company's focus on wet AMD and DME, significant markets with unmet needs, presents a substantial opportunity. Key value drivers include positive Phase 3 trial results for OPT-302, potential FDA approval, and subsequent market penetration. The current market capitalization of $0.60 billion, coupled with a negative P/E ratio of -2.12, reflects the company's pre-revenue status and reliance on future clinical and commercial success. Upcoming clinical trial readouts will be critical catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established therapies.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.60B reflects investor valuation of Opthea's pipeline and potential.
- Gross Margin of 100.0% indicates strong potential profitability upon commercialization, although currently based on limited revenue.
- Negative P/E Ratio of -2.12 due to the company's current lack of profitability as a clinical-stage biopharmaceutical company.
- OPT-302 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME).
- Beta of 1.72 suggests higher volatility compared to the overall market, typical for biotechnology companies.
Competitors & Peers
Strengths
- Novel VEGF-C/D inhibitor mechanism of action.
- Clinical-stage development of OPT-302.
- Strong intellectual property portfolio.
- Focus on significant unmet needs in retinal diseases.
Weaknesses
- Reliance on a single lead asset (OPT-302).
- Limited financial resources as a clinical-stage company.
- Lack of commercial infrastructure.
- High risk of clinical trial failure.
Catalysts
- Upcoming: Phase 3 clinical trial results for OPT-302 in wet AMD.
- Upcoming: Potential FDA approval of OPT-302.
- Ongoing: Strategic partnerships with larger pharmaceutical companies.
- Ongoing: Expansion of the intellectual property portfolio.
- Ongoing: Development of additional pipeline candidates.
Risks
- Potential: Clinical trial failures for OPT-302.
- Potential: Regulatory hurdles and delays.
- Potential: Competition from established VEGF-A inhibitors.
- Potential: Patent expiration.
- Ongoing: Reliance on a single lead asset (OPT-302).
Growth Opportunities
- Expansion into New Geographic Markets: Opthea has the opportunity to expand its market reach beyond Australia, particularly into the United States and Europe, pending regulatory approvals for OPT-302. The global market for AMD treatments is projected to reach billions of dollars, offering a significant revenue opportunity for Opthea if it can successfully commercialize its product in these key regions. Timeline: 3-5 years post-approval.
- Development of Additional Pipeline Candidates: Opthea can leverage its expertise in VEGF biology to develop additional pipeline candidates targeting other retinal diseases or related conditions. This would diversify the company's product portfolio and reduce its reliance on OPT-302. The market for novel ophthalmic therapies is continuously growing, driven by unmet medical needs. Timeline: 5-7 years.
- Strategic Partnerships and Collaborations: Opthea can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of OPT-302. Collaborations can provide access to additional funding, expertise, and distribution networks. The biotechnology industry is characterized by frequent partnerships, allowing companies to share risks and resources. Timeline: Ongoing.
- Combination Therapies: Opthea can explore the potential of OPT-302 in combination with other existing therapies for AMD and DME. Combination therapies may offer improved efficacy and address different aspects of the disease pathology. The market for combination therapies is growing, as clinicians seek more effective treatment options. Timeline: 2-4 years.
- Expansion into Diabetic Retinopathy: Opthea can expand the application of OPT-302 to include diabetic retinopathy, another major cause of vision loss in diabetic patients. The market for diabetic retinopathy treatments is substantial and growing, driven by the increasing prevalence of diabetes worldwide. This expansion would broaden the potential market for OPT-302 and increase its revenue potential. Timeline: 3-5 years.
Opportunities
- Positive Phase 3 trial results for OPT-302.
- Partnerships with larger pharmaceutical companies.
- Expansion into new geographic markets.
- Development of additional pipeline candidates.
Threats
- Competition from established VEGF-A inhibitors.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Patent expiration.
Competitive Advantages
- Intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3.
- First-in-class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors.
- Clinical stage development of OPT-302, a novel therapy for wet AMD and DME.
- Proprietary knowledge and expertise in VEGF biology.
About CKDXF
Opthea Limited, founded in 1984 and formerly known as Circadian Technologies Limited until December 2015, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for eye diseases. Headquartered in South Yarra, Australia, Opthea's core focus lies in addressing unmet needs in the treatment of retinal diseases. The company's primary asset is OPT-302, a soluble form of VEGFR-3 currently undergoing clinical development. OPT-302 is being investigated as a novel therapy for wet neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Opthea's intellectual property portfolio covers Vascular Endothelial Growth Factors (VEGF) including VEGF-C, VEGF-D, and VEGF Receptor-3, targeting diseases associated with blood and lymphatic vessel growth and vascular leakage. The company aims to provide first-in-class VEGF-C/D inhibitors for treatment in combination with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. Opthea operates primarily in Australia, focusing on research, development, and eventual commercialization of its ophthalmic therapies.
What They Do
- Develops therapies for eye diseases.
- Focuses on Vascular Endothelial Growth Factors (VEGF) related treatments.
- Creates therapies for blood and lymphatic vessel growth related diseases.
- Develops treatments for vascular leakage.
- Lead asset is OPT 302, a soluble form of VEGFR 3.
- OPT 302 is in clinical development for wet neovascular age related macular degeneration.
- OPT 302 is in clinical development for diabetic macular edema (DME).
- Creates first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors.
Business Model
- Develops and patents novel therapies for eye diseases.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Commercializes approved therapies directly or through partnerships.
Industry Context
Opthea Limited operates within the biotechnology industry, specifically targeting the ophthalmology market. The market for AMD and DME treatments is substantial and growing, driven by an aging population and increasing prevalence of diabetes. Competition includes established players with VEGF-A inhibitors, such as AIHLF (Alimera Sciences, Inc.) and AMGXF (Amgen Inc.). Opthea aims to differentiate itself with OPT-302, a VEGF-C/D inhibitor, potentially offering a novel approach to treating these diseases. The biotechnology industry is characterized by high risk and high reward, with significant investments in research and development and regulatory hurdles.
Key Customers
- Patients with wet neovascular age-related macular degeneration (AMD).
- Patients with diabetic macular edema (DME).
- Ophthalmologists and retinal specialists.
- Hospitals and clinics.
Financials
Chart & Info
Opthea Limited (CKDXF) stock price: Price data unavailable
Latest News
No recent news available for CKDXF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CKDXF.
Price Targets
Wall Street price target analysis for CKDXF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CKDXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeremy Max Levin Ba Zoology Dphil Mb Bchir
CEO
Jeremy Max Levin brings a wealth of experience in the pharmaceutical and biotechnology industries. He holds a Ba in Zoology, a Dphil, and an Mb Bchir. Prior to joining Opthea, he held leadership positions at several prominent pharmaceutical companies, including Bristol-Myers Squibb and Teva Pharmaceutical Industries. His expertise spans drug development, commercialization, and strategic partnerships.
Track Record: Under Jeremy Max Levin's leadership, Opthea has focused on advancing the clinical development of OPT-302 and securing strategic partnerships. Key milestones include the initiation of Phase 3 clinical trials for OPT-302 and the expansion of the company's intellectual property portfolio. He has overseen the company through critical funding rounds and strategic shifts.
CKDXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Opthea Limited (CKDXF) may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited reporting requirements, potentially leading to less transparency for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with distressed financials, early-stage ventures, or those that choose not to comply with stricter listing standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure requirements increase information asymmetry.
- Lower trading volume and liquidity can lead to price manipulation.
- Higher potential for fraud or scams compared to exchange-listed companies.
- OTC Other companies may have difficulty raising capital.
- Delays in reporting financial information.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements (if available).
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Monitor news and press releases for any red flags.
- Consult with a financial advisor before investing.
- Clinical-stage development of OPT-302.
- Focus on significant unmet needs in retinal diseases.
- CEO with experience in the pharmaceutical industry.
- Intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3.
- Company was incorporated in 1984.
Common Questions About CKDXF
What does Opthea Limited do?
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for eye diseases, primarily wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Its lead asset, OPT-302, is a novel VEGF-C/D inhibitor designed to be used in combination with existing VEGF-A inhibitors. The company aims to provide improved treatment options for patients suffering from these debilitating retinal diseases, addressing significant unmet medical needs in the ophthalmology market.
What do analysts say about CKDXF stock?
Analyst coverage of CKDXF is pending, reflecting the company's current stage of development and OTC listing. Key valuation metrics will likely focus on the potential market size for OPT-302, the probability of clinical trial success, and the potential for future revenue generation. Growth considerations include the successful commercialization of OPT-302 and the expansion of the company's pipeline. Investors should conduct their own due diligence and consider the risks associated with investing in a clinical-stage biopharmaceutical company.
What are the main risks for CKDXF?
The main risks for Opthea Limited include the potential failure of OPT-302 in clinical trials, regulatory hurdles and delays in obtaining FDA approval, competition from established VEGF-A inhibitors, and the risk of patent expiration. As a clinical-stage company, Opthea is heavily reliant on the success of its lead asset, and any setbacks in its development could significantly impact the company's value. Additionally, the company faces the challenge of securing funding to support its ongoing research and development activities.
What are the key factors to evaluate for CKDXF?
Opthea Limited (CKDXF) currently holds an AI score of 53/100, indicating moderate score. Key strength: Novel VEGF-C/D inhibitor mechanism of action.. Primary risk to monitor: Potential: Clinical trial failures for OPT-302.. This is not financial advice.
How frequently does CKDXF data refresh on this page?
CKDXF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CKDXF's recent stock price performance?
Recent price movement in Opthea Limited (CKDXF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel VEGF-C/D inhibitor mechanism of action.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CKDXF overvalued or undervalued right now?
Determining whether Opthea Limited (CKDXF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CKDXF?
Before investing in Opthea Limited (CKDXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.